Abbott's Q2 Surge: A Stronger Pulse in Devices and Diagnostics Outshines Revenue Miss

Related Articles

What Drove Ericsson's Q1 2026 Revenue Miss

4 months ago

What's Driving Cardio Diagnostics Holdings' Recent Stock Surge

6 months ago

What's the Retail Pulse Ahead of Q4 Earnings

5 months ago

What Drove AutoZone's Q3 Earnings Beat Amidst a Revenue Miss

3 months ago

Category

You may also like

Stock News•2 weeks ago

Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst

Abbott's Medical Devices arm is a growth catalyst, driven by electrophysiology, expanding CGM adoption, and a cardiovascular pipeline extending into 2029 and beyond.

ABT

Share

Stock News•1 months ago

Abbott Laboratories: Double Beat And Raise Surprises The Street (Rating Upgrade)

Abbott Laboratories surged 14% after Q2 results beat expectations and FY 2026 guidance was raised. Diagnostics and electrophysiology posted robust growth, with shareholder returns totaling $2.1 billio...

ABT

Share

Stock News•1 months ago

Unlocking Q2 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics

Abbott (ABT) Q2 2026 estimates are being evaluated beyond revenue and EPS, with analysts projecting key operational metrics for the quarter ended June 2026.

ABT

Share